Nanochon, an orthopedic device company, closed a $4.1 million Seed Prime II funding round.
The company is developing an implant for treating cartilage defects in the knee. The funding will be used for its first in-human clinical study for the implant, according to a Jan. 12 cultivate(MD), which led the funding round.
The phase 1 trial will evaluate the efficacy and safety of the company’s Chondrograft knee implant in a 10 patient study.
In total, Nanochon has raised $11.3 million in capital, the release said.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
